Autologous versus allogeneic: how cell therapy development is changing in oncology
Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
Themes
CinnaGen Enters EU Market with EMA Approval for Zandoriah®
SLE and LN market expected to reach $5.9bn across 7MM by 2034
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success
Big pharma and investors re-engage in CGTs and race to scale
Investors bet on newer technology and indications for CGTs
Redefining clinical trials in oncology and rare diseases across the Europe
Metagenomi culls 25% of its workforce and replaces CEO in reshuffle
